Publications by authors named "T Franchina"
While recent randomized controlled trials (RCT) have suggested superior overall survival (OS) outcomes with segmentectomy over lobectomy, questions remain regarding the comparability of these surgical procedures for treating early-stage non-small cell lung cancer (NSCLC). This systematic review and meta-analysis aimed to synthetize existing evidence and to compare the survival outcomes observed for stage IA NSCLC following segmentectomy or lobectomy. 40 studies (38 observational, 2 RCTs) encompassing 103,926 patients were analyzed.
View Article and Find Full Text PDFArticle Synopsis
- Monoclonal antibodies (mAbs) like daratumumab and elotuzumab have greatly improved treatment for multiple myeloma (MM), but their neuropsychiatric safety lacks sufficient post-marketing data.
- This study utilized the FDA Adverse Events Reporting System (FAERS) database to analyze neuropsychiatric adverse events (AEs) linked to mAbs for MM from 2015 to 2023.
- The analysis uncovered significant signals of disproportionate reporting (SDRs) for various neuropsychiatric issues associated with these drugs, indicating a need for further research into their safety profiles, particularly for conditions like Guillain-Barre syndrome (GBS).
Background: Increasing evidence suggests that diabetes increases the risk of developing different types of cancer. Hyperinsulinemia, hyperglycemia and chronic inflammation, characteristic of diabetes, could represent possible mechanisms involved in cancer development in diabetic patients. At the same time, cancer increases the risk of developing new-onset diabetes, mainly caused by the use of specific anticancer therapies.
View Article and Find Full Text PDFEndocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group.
Cancer Treat Rev
May 2024
Article Synopsis
- Immunotherapy using immune checkpoint inhibitors (ICI) is becoming common in cancer treatment, but managing related endocrine side effects can be challenging.
- Different scientific societies have varying guidelines concerning when to conduct endocrine testing for patients undergoing this therapy.
- A panel of experts from several Italian medical associations has developed a straightforward and practical checklist for assessing endocrine and metabolic health in cancer patients receiving immunotherapy.
Cancer management has significantly evolved in recent years, focusing on a multidisciplinary team approach to provide the best possible patient care and address the various comorbidities, toxicities, and complications that may arise during the patient's treatment journey. The co-occurrence of diabetes and cancer presents a significant challenge for health care professionals worldwide. Management of these conditions requires a holistic approach to improve patients' overall health, treatment outcomes, and quality of life, preventing diabetes complications and cancer treatment side-effects.
View Article and Find Full Text PDF